Organon & Co. (NYSE:OGN) Shares Gap Up – Time to Buy?

Shares of Organon & Co. (NYSE:OGN) gapped up before the market opened on Thursday . The stock had previously closed at $9.21, but opened at $9.67. Organon & Co. shares last traded at $9.3070, with a volume of 3,069,525 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Barclays upped their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a report on Tuesday, February 24th. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, Organon & Co. has an average rating of “Reduce” and a consensus price target of $8.50.

Organon & Co. Stock Up 0.9%

The company has a market capitalization of $2.42 billion, a PE ratio of 13.12, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47. The firm has a 50-day moving average of $6.97 and a two-hundred day moving average of $7.71.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.10). The business had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The company’s revenue was down 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.90 earnings per share. Equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.9%. The ex-dividend date was Monday, February 23rd. Organon & Co.’s dividend payout ratio is presently 11.27%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OGN. AQR Capital Management LLC lifted its stake in Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Vanguard Group Inc. lifted its stake in Organon & Co. by 11.3% during the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after purchasing an additional 3,650,860 shares in the last quarter. UBS Group AG lifted its stake in Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. Private Management Group Inc. lifted its stake in Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its stake in Organon & Co. by 102.1% during the third quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after purchasing an additional 1,131,941 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.